➡️ Death has always fascinated human civilisations
➡️ Not just the ending of a life, but either preparation for the afterlife or attempts to restore an existing life
A 🧵
1/28
➡️ Ancient Egyptians preserved corpses via mummification for an afterlife
➡️ They removed internal organs, used embalming fluids, linen bandages, & intricate coffins
➡️ The wealthy had pyramids
➡️ Relatives, staff & pets were buried alive for the journey to the afterlife
2/28
➡️ In Greek Mythology, the River Styx separated the worlds of the living & dead
➡️ Charon, the Ferryman, required payment from the deceased for passage
➡️ The dead were buried with a coin
➡️ Those unable to pay were left to wander the river bank for 100 years
3/28
➡️ Mary Shelley's classic novel Frankenstein explored the theme of overcoming death
➡️ Dr Frankenstein created a living being by assembling body parts from the deceased
➡️ As a child, Shelly was fascinated by stories of electrical currents stimulating movement in corpses
4/28
➡️ The modern management of cardiac arrest mirrors these themes
➡️ Resuscitation enables life to be snatched from the jaws of death
➡️ Post arrest management potentially allows the person to be saved
➡️ Many interventions have been tested
5/28
➡️ Based on incredible stories of survival after prolonged immersion in freezing water or snow, hypothermia has been extensively investigated post arrest
➡️ Led by the TTM trials, numerous high quality studies have failed to convincingly demonstrate benefit from cooling
6/28
➡️ Barbituates were developed by Adolf von Baeyer in 1864
➡️ They were introduced into clinical practice in 1904 for treatment of sleep disorders, seizures, and psychoses
➡️ The name barbituates may have come in honour of von Baeyer's friend Barbara
7/28
➡️ In 1986, thiopental was tested post cardiac arrest
➡️ 262 comatose survivors were randomised to 1 dose of 30 mg/kg or placebo
➡️ 1 year outcomes were similar
🔴 survival - 77 v 80%
🔴 neuro recovery - good 20 v 15% | poor 2 v 5%
➡️ Neither did it work taken pre-arrest
8/28
➡️ Xenon was discovered in 1898 by British chemists William Ramsay & Morris Travers
➡️ It was first used clinically as an anaesthetic agent in 1951 by American Stuart Cullen
➡️ In animal models, xenon has neuroprotective effects post cardiac arrest
9/28
➡️ Xenon was tested in 2016 in 110 comatose patients after OHCA
➡️ Patients were randomised to inhaled xenon or not
➡️ Both groups were treated at 33C
➡️ Xenon resulted in
🔴 less white matter damage
🔴 similar functional outcomes
🔴 similar mortality at 6/12 (27% vs 34%)
10/28
➡️ Exenatide is a glucagon-like peptide-1 analog used for the management of diabetes mellitus
➡️ It was first isolated by John Eng in 1992
➡️ Exenatide has various neuroprotective effects, including reducing cerebral infarction volume
11/28
➡️ It was tested in an RCT in 2016
➡️ 120 comatose patients after out-of-hospital cardiac arrest were randomised to exenatide or placebo
➡️ Brain injury, as measured by neuron specific enolase levels, were similar between groups
➡️ Functional outcomes were also similar
12/28
➡️ Calcium channel blockers may limit the ischaemia-induced entry of calcium into cells
➡️ Nimodipine is widely used in aneurysmal subarachnoid haemorrhage for the prevention of delayed cerebral ischaemia
➡️ However, the exact mechanism of action in aSAH remains unclear
13/28
➡️ in 1990, 155 patients after out-of-hospital VF cardiac arrest were randomised to IV nimodipine or placebo
🔴 One year survival was similar (40% vs 36%)
🔴 Nimodipine resulted in less recurrent VF
14/28
➡️ Lidoflazine is also a calcium channel blocker
➡️ A trial in 1991 randomised 520 comatose cardiac arrest survivors to lidoflazine or placebo
➡️ 6 month outcomes were similar
🔴 survival - 82 v 83%
🔴 neuro recovery - good 15 v 13% | poor 1.2 v 1.9%
15/28
➡️ A hormone was first postulated as an erythropoiesis stimulating agent in 1905 by Paul Carnot
➡️ Erythropoietin has a range of effects across different tissues
➡️ The brain has Epo receptor–expressing cells & erythropoietin may have potential neuroprotective effects
16/28
➡️A French trial randomised 476 patients post OHCA to IV erythropoietin or not
➡️5 IV doses of 40K units were given
🔴At day 60, the % with CPC scores of 1 were similar in each group - 32% v 32%
🔴The epo group suffered more adverse events, including thromboses (12 v 6%)
17/28
➡️ Although adequate cerebral perfusion is necessary for neuronal activity, the optimal blood pressure post cardiac arrest is unknown
➡️ Targeting too high a pressure risks further myocardial damage
➡️ Too low a pressure risks cerebral ischaemia
18/28
➡️ In 2022, the BOX trial compared mean arterial pressure targets of 77 with 63 mmHg in 789 pts post OHCA
➡️ Outcomes were similar between groups
🔴 Composite primary outcome of death or poor neuro recovery (34% vs 32%)
🔴 Day 90 mortality 31% v 29%
19/28
➡️ Hyperoxia has been associated with worse outcomes across a range of conditions, including cardiac arrest
➡️ By targeting a lower oxygen level, hyperoxia may be avoided
➡️ However, hypoxia's not great either for an injured brain....
20/28
➡️2 large trials were published in 2022 investigating oxygenation post cardiac arrest
➡️The Australian EXACT trial compared SpO2s of 90-94% with 98-100% in 428 pts
➡️The Danish BOX trial compared 9-10 with 13-14 kPa in 789 pts
🔴Group outcomes were similar in both trials
21/28
➡️ Carbon dioxide has many physiological effects relevant to cardiac arrest
➡️ It is a major determinant of cerebral blood flow, potentially increasing cerebral perfusion without use of injurious catecholamines
➡️ It is also anticonvulsant, anti-inflammatory & antioxidant
22/28
➡️The Finnish COMACARE trial examined low (4.5–4.7) & high (5.8–6.0 kPa) PaCO2 in 120 patients post OHCA
🔴Median serum NSE levels were similar at 48 hours - 18.8 v 22.5 μg/l
🔴Notably, the median cerebral oxygen saturation was higher in the high-normal PaCO2 group
23/28
➡️ The Australian pilot CCC trial also compared low (4.7-6.0) & high (6.7-7.3 kPA) PaCO2 levels in 86 patients post cardiac arrest
➡️ The trial demonstrated the intervention was feasible & safe
24/28
➡️ With other interventions proving disappointing, the role for targeted therapeutic mild hypercapnia remains open
➡️ Any effective therapy would be significant
🔴 > 356,000 OHCAs in the USA pa
🔴 <50% who reach hospital survive
🔴 7% survive with good neuro recovery
➡️ There are ~ 5.8 million trauma deaths per year globally
➡️ Trauma is the largest cause of death below the age of 50
➡️ One-third of severely injured trauma patients are coagulopathic at hospital arrival
➡️ Fibrinogen is often used, but is it effective?
a short 🧵
1/10
➡️ Trauma-induced coagulopathy is due to inflammation & shock
➡️ It is worsened by hypothermia, acidosis, and hemodilution
➡️ Coagulopathy due to hemorrhage is strongly associated with mortality
➡️ 1/3 of early trauma deaths are due to uncontrolled haemorrhage
2/10
➡️ Fibrinogen is depleted early during major bleeding
➡️ It can be replaced with fresh frozen plasma, cryoprecipitate or fibrinogen concentrate
➡️ Cryoprecipitate includes fibrinogen, factor VIII coagulant, von Willebrand factor, fibronectin & factor XIII
➡️It's widely used for treatment & prevention of haemorrhage
➡️It's in the WHO's List of Essential Medicines & recommended in the European Traumatic Haemorrhage guideline (2023)
➡️But is it as efficacious as we think?
🧵 1/17
🚩 History
➡️Drs. Utako & Shosuke Okamoto invented TXA in 1962
➡️They identified that the amino acid lysine inhibited the degradation of plasmin, a profibrinolytic enzyme
➡️Lysine was modified to first produce Epsilon- Amino-Caproic Acid and later TXA, x 27 more potent
2/17
🚩 Pharmacology
➡️TXA is a molecular analog of lysine
➡️It inhibits fibrinolysis by preventing the binding of plasminogen to fibrin
➡️This inhibits plasmin formation & displaces plasminogen from the fibrin surface
➡️It also has effects on the immune system & inflammation
➡️ REBOA is an exciting "new" therapy for non-compressible torso haemorrhage
➡️ It's used across the world, but without robust evidence
➡️ Does it work? Is it beneficial?
➡️ A thread...
2/13
🚩 Uncontrollable haemorrhage accounts for
➡️ > 80% of combat deaths
➡️ ~ 40% of civilian trauma-related deaths
🚩 Many have been determined to be preventable deaths
🚩 ~ 67% of fatal bleeding occurs in the torso region
3/13
Emergency thoracotomy (ET) has a long history in resuscitation
🚩 1880 - Paul Niehans first documented ET in human cardiac arrest
🚩 1901 - Kristian Ingelsrud performed the first successful resuscitation
🚩 1953 - Stephenson had 28% survival in 1200 cardiac arrests
➡️Carl Wilhelm Scheele, a German-Swedish pharmaceutical chemist, first identified oxygen in 1771
➡️By heating mercuric oxide, silver carbonate, magnesium nitrate, & other salts, he produced “fire air”
2/16
@DogICUma@VR_Cornelius@BodilSRasmussen@JonathanCaseyMD@toddrice_ICU ➡️although Scheele discovered oxygen & other elements, including hydrogen & chlorine, others were credited with these novel findings
➡️he received the moniker “hard luck Scheele”
➡️he then died from mercury poisoning
➡️The history of resuscitation in cardiac arrest is long and fascinating
➡️Over time, four components have emerged to provide the central basis for saving an apnoeic, pulseless person just minutes from death
A thread.....
1/30
➡️Perhaps the earliest reference to artificial breathing comes from the Egyptian Goddess Isis
➡️She resuscitated her dead husband (who was also her brother...) by breathing into his mouth
2/30
➡️The Greek physician Galen was the first to describe artificial ventilation with his famous quote:
➡️"If you take a dead animal & blow air through its larynx through a reed, you will fill its bronchi and watch its lungs attain the greatest distention"